Bottom line
Is OZEM a good fund? The bottom line
OZEM is an actively managed large blend ETF from Roundhill.
Its expense ratio is 0.59% — about $59 a year on every $10,000 invested, cheaper than 71% of large blend funds we track.
It returned +41.4% over one year (as of Dec 31, 2025, per its prospectus).
With $54.1 million in net assets and 26 holdings, its largest position is Novo Nordisk A/S (13.0%) and the top 10 make up 72% of the portfolio.
What to watch
- Concentrated: top 10 holdings are 72% of assets
Updated Nov 19, 2026
What OZEM invests in
The Fund seeks to provide capital appreciation.
The Fund is an actively managed exchange-traded fund (ETF) that pursues its investment objective by seeking to provide exposure to companies involved in the development of pharmaceutical drugs and/or supplements that can be utilized to help individuals lose weight, maintain an ideal weight, and/or maintain body composition during weight loss (GLP-1 & Weight Loss Drugs). The Fund will focus its investments in the securities of companies that are the acknowledged leaders in the development of GLP-1 & Weight Loss Drugs, which it defines as those companies that have GLP-1 & Weight Loss Drugs currently undergoing Phase I, Phase II, and/or Phase III of U.S. Food & Drug Administration (FDA) clinical trials and in securities of companies with GLP-1 & Weight Loss Drugs that have been approved by the FDA (GLP-1 & Weight Loss Companies). For non-U.S. companies that are not subject to oversight by…
From the fund's prospectus (filed Apr 30, 2026).
OZEM performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| OZEM | +41.4% | — | — |
| Large Blend median | +13.8% | +9.7% | +10.9% |
Source: Fund prospectus, as of Dec 31, 2025
What OZEM costs
On a $10,000 investment, OZEM's 0.59% expense ratio costs about $59 a year. The prospectus estimates $738 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.
OZEM top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Novo Nordisk A/S NVO | 12.96% |
| 2 | Eli Lilly & Co LLY | 12.69% |
| 3 | Mount Vernon Liquid Assets Portfolio, LLC | 9.93% |
| 4 | Pfizer Inc PFE | 6.38% |
| 5 | Kailera Therapeutics Inc KLRA | 6.21% |
| 6 | Viking Therapeutics Inc VKTX | 5.86% |
| 7 | CSPC Pharmaceutical Group Ltd 1093 | 5.32% |
| 8 | Chugai Pharmaceutical Co Ltd 4519 | 4.51% |
| 9 | Ascletis Pharma Inc 1672 | 4.20% |
| 10 | Zealand Pharma A/S ZEAL | 3.92% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 72% of the fund. See all top 25 holdings and asset mix →